Therapeutic antibody (Tixagevimab; AZD8895, shown in gold) docked against the new viral variant (SARS-CoV-2 XBB.1.5 receptor binding domain, shown in green)
Computational workflow of the predictive analyses from sequence, to protein structure generation, to protein-antibody docking. The red circles indicate the areas of structural interaction between the receptor binding domain (RBD) of the viral protein and the fragment antigen binding (Fab) region of the antibodies.